Company

Rege Nephro Co., Ltd.

Biotechnology Research Sakyo-ku, Jp 12 employees

Employees: 12

www.regenephro.co.jp LinkedIn Crunchbase

Rege Nephro Co., Ltd. Overview

Headquarters: Sakyo-ku, Jp
Website: www.regenephro.co.jp
Industry: Biotechnology Research
Employees: 12
Founded: 2019
Funding: 15.2M
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

藤沢市

About Rege Nephro Co., Ltd.

Rege Nephro is a clinical-stage biotech company developing cell therapy for chronic kidney disease (CKD) and small molecule for autosomal dominant polycystic kidney disease (ADPKD), and founded in 2019. There are 13 million patients with CKD in Japan, of which 340,000 are severe CKD patients forced to undergo artificial dialysis. The healthcare cost of dialysis is $12 billion, 4% of the total healthcare cost of Japan. However, there is still no curative treatment for CKD. Rege Nephro tries to treat patients suffering from CKD with cell therapy using nephron progenitor cells differentiated from iPS cells.

Rege Nephro Co., Ltd. Contact Details

People in AeroLeads: 4

Rege Nephro Co., Ltd. Org Chart

Sample employees and titles

Name	Title	Location	Contact
Hiraku Tsujimoto	Rege Nephro Co., Ltd. & Center for Ips	Hyogo, Japan	View
Akifumi Morinaka	CEO - Rege Nephro	Kyoto, Japan	View
Norihide Hayakawa	Dci Partners (Vc) - Director	Tokyo, Japan	View
Lucia Tomiyama	Regenerative Medicine, Drug Discovery	Kyoto, Japan	View